Real questions from health communities, answered with cited research from PubMed and Vellito's article corpus. Plain language, no medical advice. How this works.
Yes, CAR-T cell therapy is highly effective for hematologic malignancies, with success in blood cancers like ALL, but faces challenges in solid tumors.
The aMAP risk score is associated with increased mortality in patients with alcohol-related liver disease.
Osimertinib is effective for EGFR-mutated NSCLC patients with active brain metastases, with real-world data showing median progression-free survival of 12.4 months and…
Yes, a high neutrophil-to-lymphocyte ratio (NLR) is linked to a higher risk of developing brain metastasis in lung cancer patients, according to a meta-analysis and other studies.
Lung cancer brain metastasis is driven by tumor cells co-opting brain developmental pathways, secreting exosomal CEMIP and LCN2, and recruiting astrocytes and macrophages to…
Yes, stereotactic radiotherapy is an effective treatment for brain metastases, offering high local control rates and preserving cognitive function.
Endobronchial access has the lowest inaccurate placement rate and low complication risk, making it a strong choice for fiducial marker insertion before lung cancer radiation.
Brain metastases are common in lung cancer, especially small cell (15% at diagnosis) and non-small cell types, with elevated neutrophil-to-lymphocyte ratio as a risk factor…
Yes, a high neutrophil-to-lymphocyte ratio (NLR) is an independent risk factor for brain metastasis in lung cancer, according to a meta-analysis of 14 studies.
Datopotamab deruxtecan did not improve overall survival compared to chemotherapy in metastatic HR-positive breast cancer, despite improving progression-free survival.
Yes, trastuzumab deruxtecan improves progression-free survival compared to chemotherapy in HR-positive, HER2-low breast cancer, but overall survival data are not yet mature.
Yes, early evidence suggests dose intensification to visible tumors may improve outcomes for intermediate- or high-risk prostate cancer, but ongoing trials will clarify safety…
Yes, enzalutamide plus ADT significantly improves survival in metastatic hormone-sensitive prostate cancer, with a 34% reduction in risk of death and a 5-year survival rate of…
Yes, research on macrophage polarization in prostate cancer has grown significantly since 2015, with studies exploring its role in tumor progression and therapy resistance.
Specific mutations like KRAS, BRAF, and MMR status strongly influence treatment response in colorectal cancer, guiding targeted therapy and immunotherapy decisions.
Quality of life for colorectal cancer survivors is influenced by physical symptoms, psychological distress, social support, self-efficacy, and demographic factors like age and…
AI in colorectal cancer treatment faces challenges including data quality and privacy issues, lack of generalizability, interpretability problems, and regulatory validation…
Gut microbiota imbalances, including harmful bacteria like Fusobacterium nucleatum, can promote colorectal cancer through inflammation, DNA damage, and immune disruption, while…
Yes, home exercise may help reduce fatigue and anxiety in colorectal cancer patients, but the evidence is low certainty and more research is needed.
New treatments for triple-negative breast cancer include chemo-immunotherapy (pembrolizumab plus platinum-based chemo) and potential NY-ESO-1 targeted therapies; for…
Yes, early research shows plasma lipid panels can help detect early-stage breast cancer, with machine learning models achieving high accuracy, but they are not yet standard…
Yes, deep learning can help doctors find breast cancer on tomosynthesis scans, matching or improving radiologist accuracy in some cases.
Yes, AI is being researched for breast cancer pathology, including digital pathology, deep learning for imaging, and machine learning for biomarker detection.
Yes, the PECS II block significantly reduces morphine use after breast cancer surgery, based on multiple randomized trials and a meta-analysis.
We pull real patient questions from public Reddit health communities (r/AskDocs, r/diabetes, r/menopause, etc.). Each question is rewritten into a generic medical question (no personal details), then answered by an AI using only cited sources from Vellito's article database and PubMed. A second AI independently scores each answer for accuracy and citation fidelity before publication. Answers below the safety threshold or touching emergency, dosing, or pediatric topics are queued for human review and never auto-published.
This is not medical advice. Always speak with your own doctor before making decisions about your health.